middle.news
Emyria Puts Australian Psychedelic Care Model Before US FDA
9:15am on Wednesday 16th of September, 2026 AEST
•
Healthcare
Read Story
Emyria Puts Australian Psychedelic Care Model Before US FDA
9:15am on Wednesday 16th of September, 2026 AEST
Key Points
In-person presentation at the FDA’s 14 September public hearing
Australian experience spans governance, training, safety and evidence collection
US opportunities under assessment across partnerships, research and treatment delivery
No regulatory approval, commercial agreement or quantified financial benefit announced
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Emyria (ASX:EMD)
OPEN ARTICLE